Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2024-01-04 00:00:00 ET · period of report 2024-01-02 · accession 0002001011-24-000009 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-01-04 | 2024-01-02 | LGND | Korenberg Matthew E | Pres, CHIEF OPERATING | F - Tax | $72.31 | -2,917 | 94.2K | -3% | -$210.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-02 | F | D | 2,917 | $72.31 | 94,223 | D | — | — | (F1) Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. |